ACM
JBIO

Aster Capital Management’s Jade Biosciences JBIO Stock Holding History

Aster Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-95
Closed -$1.47K – 865
2025
Q4 		$1.47K Buy
+95
New +$1.11K ﹤0.01% 986

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Aster Capital Management's JBIO Position: Q1 2026 in Review

Aster Capital Management sold out of Jade Biosciences (JBIO) in Q1 2026, closing a stake of 95 shares — an estimated $1.47K sold.

Aster Capital Management first reported a position in JBIO in Q4 2025 and held it in 1 quarter. The position peaked at $1.47K in Q4 2025. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • Aster Capital Management reported no remaining Jade Biosciences position as of Q1 2026 after selling out during the quarter.
  • Aster Capital Management sold 95 Jade Biosciences shares in Q1 2026, an estimated $1.47K.
  • Aster Capital Management first reported a position in Jade Biosciences in Q4 2025 and held it in 1 quarter.
  • Aster Capital Management's Jade Biosciences position peaked at $1.47K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.